AAPL325.89-1.85 (-0.56%) ▼|ABBV253.29-2.81 (-1.10%) ▼|ABT100.60+0.93 (+0.93%) ▲|ACN140.09-0.77 (-0.55%) ▼|ADBE218.36-8.80 (-3.87%) ▼|AMAT553.92-10.63 (-1.88%) ▼|AMD552.33+7.90 (+1.45%) ▲|AMGN366.05-0.19 (-0.05%) ▼|AMT166.06+2.67 (+1.63%) ▲|AMZN244.85-2.70 (-1.09%) ▼|AVGO396.81+10.31 (+2.67%) ▲|AXP348.74-2.05 (-0.58%) ▼|BA208.65+3.85 (+1.88%) ▲|BAC61.62+0.40 (+0.65%) ▲|BKNG177.86-1.54 (-0.86%) ▼|BLK1,056.63+18.39 (+1.77%) ▲|BMY60.76-0.17 (-0.28%) ▼|BNY160.39+1.50 (+0.94%) ▲|BRK-B489.39-0.26 (-0.05%) ▼|C132.25-0.59 (-0.44%) ▼|CAT889.31-0.66 (-0.07%) ▼|CL91.63+1.13 (+1.25%) ▲|CMCSA23.52-0.29 (-1.22%) ▼|COF201.36-4.86 (-2.36%) ▼|COP118.79+1.29 (+1.10%) ▲|COST927.31-1.91 (-0.21%) ▼|CRM163.00-7.06 (-4.15%) ▼|CSCO112.21+0.03 (+0.03%) ▲|CVS108.08-2.52 (-2.28%) ▼|CVX192.98+1.91 (+1.00%) ▲|DE607.33+20.45 (+3.48%) ▲|DHR179.14+0.13 (+0.07%) ▲|DIS95.87-0.27 (-0.28%) ▼|DUK127.95+2.04 (+1.62%) ▲|EMR139.63+0.37 (+0.27%) ▲|FDX321.02+5.83 (+1.85%) ▲|GD373.16+5.43 (+1.48%) ▲|GE341.19+0.49 (+0.14%) ▲|GEV985.03-93.78 (-8.69%) ▼|GILD130.34+0.06 (+0.05%) ▲|GM82.13+2.61 (+3.28%) ▲|GOOG341.91-4.28 (-1.24%) ▼|GOOGL342.09-5.06 (-1.46%) ▼|GS1,098.20+12.64 (+1.16%) ▲|HD331.45-0.15 (-0.05%) ▼|HON232.99+3.13 (+1.36%) ▲|IBM205.77-4.73 (-2.25%) ▼|INTC102.62-2.83 (-2.68%) ▼|INTU284.47-5.45 (-1.88%) ▼|ISRG340.69-9.37 (-2.68%) ▼|JNJ255.63+5.02 (+2.00%) ▲|JPM348.21+2.98 (+0.86%) ▲|KO82.20+0.23 (+0.28%) ▲|LIN508.67+3.64 (+0.72%) ▲|LLY1,163.01-12.40 (-1.06%) ▼|LMT514.36+7.27 (+1.43%) ▲|LOW204.35+2.09 (+1.03%) ▲|LRCX319.29-2.71 (-0.84%) ▼|MA531.98-6.32 (-1.17%) ▼|MCD263.57-0.34 (-0.13%) ▼|MDLZ60.86+1.00 (+1.67%) ▲|MDT81.89-0.46 (-0.56%) ▼|META627.17-16.64 (-2.58%) ▼|MMM170.76+0.00 (+0.00%) ▲|MO72.17-0.82 (-1.12%) ▼|MRK127.47+1.21 (+0.96%) ▲|MS218.50+2.10 (+0.97%) ▲|MSFT390.34-7.41 (-1.86%) ▼|MU959.48-11.34 (-1.17%) ▼|NEE89.41+1.48 (+1.68%) ▲|NFLX68.53-0.14 (-0.20%) ▼|NKE42.21-0.75 (-1.75%) ▼|NOW95.46-6.60 (-6.47%) ▼|NVDA212.06+4.77 (+2.30%) ▲|ORCL125.84-1.21 (-0.95%) ▼|PEP135.65+0.65 (+0.48%) ▲|PFE24.82-0.12 (-0.48%) ▼|PG149.13+1.03 (+0.70%) ▲|PLTR124.57-8.09 (-6.10%) ▼|PM194.30+6.26 (+3.33%) ▲|QCOM175.63+2.13 (+1.23%) ▲|RTX194.88+1.21 (+0.62%) ▲|SBUX103.98-0.47 (-0.45%) ▼|SCHW100.80+0.84 (+0.84%) ▲|SO95.80+1.95 (+2.08%) ▲|SPG226.22-0.57 (-0.25%) ▼|T23.04+0.78 (+3.50%) ▲|TMO526.46+3.00 (+0.57%) ▲|TMUS190.94+0.17 (+0.09%) ▲|TSLA374.01-4.92 (-1.30%) ▼|TXN294.19+2.89 (+0.99%) ▲|UBER70.33-1.22 (-1.71%) ▼|UNH431.31-5.04 (-1.16%) ▼|UNP292.56-0.57 (-0.19%) ▼|UPS115.84-0.50 (-0.43%) ▼|USB64.47+0.76 (+1.19%) ▲|V353.42-2.40 (-0.67%) ▼|VZ44.29+0.51 (+1.16%) ▲|WFC86.42-1.32 (-1.50%) ▼|WMT109.33-1.06 (-0.96%) ▼|XOM154.45+2.74 (+1.81%) ▲|AAPL325.89-1.85 (-0.56%) ▼|ABBV253.29-2.81 (-1.10%) ▼|ABT100.60+0.93 (+0.93%) ▲|ACN140.09-0.77 (-0.55%) ▼|ADBE218.36-8.80 (-3.87%) ▼|AMAT553.92-10.63 (-1.88%) ▼|AMD552.33+7.90 (+1.45%) ▲|AMGN366.05-0.19 (-0.05%) ▼|AMT166.06+2.67 (+1.63%) ▲|AMZN244.85-2.70 (-1.09%) ▼|AVGO396.81+10.31 (+2.67%) ▲|AXP348.74-2.05 (-0.58%) ▼|BA208.65+3.85 (+1.88%) ▲|BAC61.62+0.40 (+0.65%) ▲|BKNG177.86-1.54 (-0.86%) ▼|BLK1,056.63+18.39 (+1.77%) ▲|BMY60.76-0.17 (-0.28%) ▼|BNY160.39+1.50 (+0.94%) ▲|BRK-B489.39-0.26 (-0.05%) ▼|C132.25-0.59 (-0.44%) ▼|CAT889.31-0.66 (-0.07%) ▼|CL91.63+1.13 (+1.25%) ▲|CMCSA23.52-0.29 (-1.22%) ▼|COF201.36-4.86 (-2.36%) ▼|COP118.79+1.29 (+1.10%) ▲|COST927.31-1.91 (-0.21%) ▼|CRM163.00-7.06 (-4.15%) ▼|CSCO112.21+0.03 (+0.03%) ▲|CVS108.08-2.52 (-2.28%) ▼|CVX192.98+1.91 (+1.00%) ▲|DE607.33+20.45 (+3.48%) ▲|DHR179.14+0.13 (+0.07%) ▲|DIS95.87-0.27 (-0.28%) ▼|DUK127.95+2.04 (+1.62%) ▲|EMR139.63+0.37 (+0.27%) ▲|FDX321.02+5.83 (+1.85%) ▲|GD373.16+5.43 (+1.48%) ▲|GE341.19+0.49 (+0.14%) ▲|GEV985.03-93.78 (-8.69%) ▼|GILD130.34+0.06 (+0.05%) ▲|GM82.13+2.61 (+3.28%) ▲|GOOG341.91-4.28 (-1.24%) ▼|GOOGL342.09-5.06 (-1.46%) ▼|GS1,098.20+12.64 (+1.16%) ▲|HD331.45-0.15 (-0.05%) ▼|HON232.99+3.13 (+1.36%) ▲|IBM205.77-4.73 (-2.25%) ▼|INTC102.62-2.83 (-2.68%) ▼|INTU284.47-5.45 (-1.88%) ▼|ISRG340.69-9.37 (-2.68%) ▼|JNJ255.63+5.02 (+2.00%) ▲|JPM348.21+2.98 (+0.86%) ▲|KO82.20+0.23 (+0.28%) ▲|LIN508.67+3.64 (+0.72%) ▲|LLY1,163.01-12.40 (-1.06%) ▼|LMT514.36+7.27 (+1.43%) ▲|LOW204.35+2.09 (+1.03%) ▲|LRCX319.29-2.71 (-0.84%) ▼|MA531.98-6.32 (-1.17%) ▼|MCD263.57-0.34 (-0.13%) ▼|MDLZ60.86+1.00 (+1.67%) ▲|MDT81.89-0.46 (-0.56%) ▼|META627.17-16.64 (-2.58%) ▼|MMM170.76+0.00 (+0.00%) ▲|MO72.17-0.82 (-1.12%) ▼|MRK127.47+1.21 (+0.96%) ▲|MS218.50+2.10 (+0.97%) ▲|MSFT390.34-7.41 (-1.86%) ▼|MU959.48-11.34 (-1.17%) ▼|NEE89.41+1.48 (+1.68%) ▲|NFLX68.53-0.14 (-0.20%) ▼|NKE42.21-0.75 (-1.75%) ▼|NOW95.46-6.60 (-6.47%) ▼|NVDA212.06+4.77 (+2.30%) ▲|ORCL125.84-1.21 (-0.95%) ▼|PEP135.65+0.65 (+0.48%) ▲|PFE24.82-0.12 (-0.48%) ▼|PG149.13+1.03 (+0.70%) ▲|PLTR124.57-8.09 (-6.10%) ▼|PM194.30+6.26 (+3.33%) ▲|QCOM175.63+2.13 (+1.23%) ▲|RTX194.88+1.21 (+0.62%) ▲|SBUX103.98-0.47 (-0.45%) ▼|SCHW100.80+0.84 (+0.84%) ▲|SO95.80+1.95 (+2.08%) ▲|SPG226.22-0.57 (-0.25%) ▼|T23.04+0.78 (+3.50%) ▲|TMO526.46+3.00 (+0.57%) ▲|TMUS190.94+0.17 (+0.09%) ▲|TSLA374.01-4.92 (-1.30%) ▼|TXN294.19+2.89 (+0.99%) ▲|UBER70.33-1.22 (-1.71%) ▼|UNH431.31-5.04 (-1.16%) ▼|UNP292.56-0.57 (-0.19%) ▼|UPS115.84-0.50 (-0.43%) ▼|USB64.47+0.76 (+1.19%) ▲|V353.42-2.40 (-0.67%) ▼|VZ44.29+0.51 (+1.16%) ▲|WFC86.42-1.32 (-1.50%) ▼|WMT109.33-1.06 (-0.96%) ▼|XOM154.45+2.74 (+1.81%) ▲|
31.1 C
New York
Wednesday, July 22, 2026

Tag: immune cells

newssourceFORcompanyinformationcontent1releasesmarket

Tethis announces application note of SmartBioSurface® slides for cell suspension workflows on leading spatial biology platform

MILAN, June 15, 2026 /PRNewswire/ -- Addressing a critical technical limitation in multi-cycle imaging - the reliable adhesion and retention of suspension-derived, non-adherent cells...

Tethis announces application note of SmartBioSurface® slides for cell suspension workflows on leading spatial biology platform

MILAN, June 15, 2026 /PRNewswire/ -- Addressing a critical technical limitation in multi-cycle imaging - the reliable adhesion and retention of suspension-derived, non-adherent cells...

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

TALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 monthsMonumenTAL-3 is the...

The Jackson Laboratory secures grant from The Michael J. Fox Foundation to advance Parkinson’s disease research through the JAX-NYSCF Collaborative

New human stem cell platform will expand access to standardized disease models, support Parkinson's disease research and therapeutic discovery efforts NEW YORK , June 9,...

CAREstream America introduces new era of science-backed innovation to deliver a new standard of quality to the US aesthetic market

CAREstream America announces an exclusive distribution partnership to bring Celltermi HS and NX Plus, an advanced probiotic-derived microbiome technology, to the US market. Celltermi...

PureHealth Research Highlights Growing Consumer Interest in Lymphatic Wellness and Botanical Support

MANASSAS, Va., June 6, 2026 /PRNewswire/ -- PureHealth Research today highlighted the growing consumer interest in lymphatic wellness and the role botanicals may play...

Mabwell’s 9MW5211 Receives IND Clearance from NMPA for Inflammatory Bowel Disease

SHANGHAI, June 4, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its independently developed innovative...

Booking Health Unveils New Study: Role of Immunotherapy in Extending Life Expectancy for Stage4 Cervical Cancer Patients

Langenfeld, Germany, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Booking Health, a global leader in medical treatment coordination, today unveiled a new study titled Role of Immunotherapy in Extending Life Expectancy for Stage 4 Cervical Cancer Patients. The report outlines how cutting-edge immunotherapy is reshaping care for women with advanced cervical cancer, offering new pathways to longer survival and improved quality of life, particularly in cases resistant to standard treatments.

CancerVax Successfully Disguises Cancer Cells and Tricks Immune Cells into Attacking Them

Recent lab results proved the Company’s hypothesis that disguising cancer cells to look like common infectious diseases can trick immune cells into attacking the malignant cells 
Recent lab results proved the Company’s hypothesis that disguising cancer cells to look like common infectious diseases can trick immune cells into attacking the malignant cells

MetrioPharm’s MP1032 Receives EMA Orphan Drug Designation in Duchenne Muscular Dystrophy

Zurich, July 29, 2025 – MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory and infectious diseases, announced today that the European Medicines Agency has granted Orphan Drug Designation (ODD) to its lead compound, MP1032 for the treatment of children affected by Duchenne muscular dystrophy (DMD). This milestone follows the U.S. FDA's ODD, underscoring MP1032's potential as a first-in-class therapy that could minimize reliance on high-dose corticosteroids, which cause severe side effects like osteoporosis, growth stunting, and metabolic issues.

BATMAN brings TCR therapy out of the shadows

COLD SPRING HARBOR, N.Y., July 28, 2025 /PRNewswire/ -- Imagine your immune cells could be modified to attack any kind of cancer. T cell...

CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in Autoimmune and Cancer Therapeutics | DelveInsight

The CD40/CD40L inhibitors market is experiencing steady growth driven by increasing research into autoimmune diseases, organ transplantation, and cancer immunotherapy. The rising prevalence of...

CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in Autoimmune and Cancer Therapeutics | DelveInsight

The CD40/CD40L inhibitors market is experiencing steady growth driven by increasing research into autoimmune diseases, organ transplantation, and cancer immunotherapy. The rising prevalence of...

Akeso Announces First Patient Enrollment in Phase III Trial of Ivonescimab for Pancreatic Cancer

HONG KONG, July 23, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsImmune cells

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers